Epistaxis Versus Nonepistaxis Bleeding in Anticoagulated Patients With Atrial Fibrillation: Results From the ENGAGE AF‐TIMI 48 Trial

Epistaxis Versus Nonepistaxis Bleeding in Anticoagulated Patients With Atrial Fibrillation: Results From the ENGAGE AF‐TIMI 48 Trial

Background Epistaxis is common with antithrombotic therapy and is often troublesome to patients, yet its frequency, severity, and outcomes are poorly characterized. Methods and Results Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarcti...

Full description

Saved in:
Bibliographic Details
Main Authors: Robert S. Semco, Regan W. Bergmark, Sabina A. Murphy, Abby L. Cange, Martin Unverdorben, Cathy Z. L. Chen, Christian T. Ruff, Elliott M. Antman, Robert P. Giugliano, Brian A. Bergmark
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
anticoagulation
atrial fibrillation
bleeding
discontinuation
epistaxis
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.123.031434
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.123.031434

Similar Items